Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1992 | Intervention-EDI and health coaching Wiki | 1.00 |
| drug1117 | CytoSorb Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051436 | Renal Insufficiency, Chronic NIH | 0.33 |
| D007674 | Kidney Diseases NIH | 0.27 |
| D002908 | Chronic Disease NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.33 |
| HP:0000077 | Abnormality of the kidney HPO | 0.27 |
| HP:0000822 | Hypertension HPO | 0.20 |
Navigate: Correlations HPO
There is one clinical trial.
Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.
Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Systolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Diastolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of systolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of diastolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.
Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS) Time: Baseline up to 12 monthsDescription: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.
Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R) Time: Baseline up to 12 monthsDescription: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.
Measure: Morisky Medication Adherence Scale (MMAS - 8) Time: Baseline up to 12 monthsDescription: Length of time provider spends with the patient. This will be compared between the intervention group and control group.
Measure: Visit Time with provider Time: Enrollment visit (baseline)Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.
Measure: Total time in clinic Time: Enrollment visit (baseline)Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.
Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) Time: Baseline up to 12 monthsDescription: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT) Time: Baseline up to 12 monthsDescription: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.
Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM) Time: Baseline up to 12 monthsDescription: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.
Measure: Perceptions of health coaching for the intervention group Time: Baseline up to 12 monthsDescription: The EMR will be reviewed to evaluate the patients medication refills for adherence.
Measure: Medication adherence from the electronic medical record (EMR) Time: Baseline up to 12 monthsDescription: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.
Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) Time: Baseline up to 12 monthsDescription: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.
Measure: Self-reported Blood Pressure-Related Behaviors Survey Time: Baseline up to 12 monthsDescription: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.
Measure: Provider Adoption based on EMR query and patient survey Time: BaselineDescription: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.
Measure: Provider Fidelity measured by EMR query Time: BaselineDescription: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.
Measure: Provider Perception of Usefulness by provider survey Time: Baseline up to 12 monthsDescription: Change in Serum Creatinine between baseline and 12-months
Measure: Change in serum creatinine Time: Baseline, 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports